Minn H, Ahonen A, Paul R
Department of Oncology and Radiotherapy, Turku University Central Hospital, Finland.
Br J Cancer. 1991 Oct;64(4):735-40. doi: 10.1038/bjc.1991.389.
Twenty patients with malignant head and neck tumours were imaged with 99Tcm-labelled hexamethylpropylene amine oxime (HMPAO), a radiopharmaceutical generally used for blood flow studies. Before radiotherapy (RT), 93% of the tumours could be detected with single photon emission computed tomography (SPECT) and 45% with planar imaging. Whole tumour-to-background 99TcmHMPAO uptake ratios ranged from 3.6 to 1.0 (mean 1.7 +/- 0.6) in untreated tumours. There was a good correlation between tumour volume and uptake (r = 0.69, P = 0.002). Sixteen patients were reimaged during or shortly after radical RT. 99TcmHMPAO uptake was significantly lower after treatment (mean uptake ratio 1.2 +/- 0.3, P less than 0.001). However, RT associated changes in 99TcmHMPAO uptake were in agreement with the clinical response in only 63% of the studies. This study indicates that 99TcmHMPAO SPECT imaging can be used for pretherapeutic localisation of head and neck tumours. Although most tumours show a decrease in uptake after irradiation the poor association with tumour regression does not allow for reliable assessment of treatment response.
20例头颈部恶性肿瘤患者用99锝标记的六甲基丙烯胺肟（HMPAO）进行成像，HMPAO是一种常用于血流研究的放射性药物。放疗（RT）前，单光子发射计算机断层扫描（SPECT）可检测出93%的肿瘤，平面成像可检测出45%的肿瘤。未经治疗的肿瘤中，肿瘤与背景的99锝-HMPAO摄取率范围为3.6至1.0（平均1.7±0.6）。肿瘤体积与摄取之间存在良好的相关性（r = 0.69，P = 0.002）。16例患者在根治性放疗期间或放疗后不久再次成像。治疗后99锝-HMPAO摄取显著降低（平均摄取率1.2±0.3，P<0.001）。然而，在仅63%的研究中，99锝-HMPAO摄取的放疗相关变化与临床反应一致。本研究表明，99锝-HMPAO SPECT成像可用于头颈部肿瘤的治疗前定位。尽管大多数肿瘤在照射后摄取减少，但与肿瘤消退的相关性较差，无法可靠评估治疗反应。
